Publications by authors named "S Sazliyana Shaharir"
Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study.
Int J Rheum Dis
January 2025
Objectives: To determine the prevalence of self-reported delayed adverse events (DAEs), major AEs, and flares following COVID-19 vaccinations among patients with autoimmune rheumatic diseases (AIRDs) in Malaysia.
Methodology: An electronically validated survey from the COVID-19 vaccination in autoimmune diseases (COVAD) study group was distributed in July 2021 to patients with autoimmune diseases and healthy controls (HCs). The survey collected data on DAEs (any AE that persisted or occurred after 7 days of vaccination), any early or delayed major adverse events (MAEs), and flares following COVID-19 vaccination.
Introduction: Heterogeneity of the clinical manifestations of systemic lupus erythematosus (SLE) may lead to diagnostic delays. This study is aimed at determining the health-seeking behaviour patterns and factors associated with diagnostic delays in a multi-ethnic SLE cohort in Malaysia.
Methodology: This was a cross-sectional study involving SLE patients who visited our institute between January 2020 and June 2021.
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.
Rheumatol Int
October 2024
Article Synopsis
- The study aimed to compare the occurrence of breakthrough COVID-19 infections (BIs) in fully vaccinated patients with systemic lupus erythematosus (SLE) against those with other rheumatic autoimmune diseases (rAIDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs).
- Results showed that 10.7% of SLE patients reported at least one BI, with frequencies similar to HCs and nrAID patients but higher than those with other rAIDs.
- Overall, vaccinated SLE patients experienced comparable levels of COVID-19 infection frequency and severity as healthy individuals, with no significant association found between demographic factors or treatments and BIs in SLE patients.
Objectives: To explore prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIM) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.
Methods: A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ≥14 days after 2 vaccine doses.
Article Synopsis
- The study investigates delayed adverse events (DAEs) from COVID-19 vaccinations in patients with systemic lupus erythematosus (SLE) compared to other autoimmune diseases and healthy individuals, with a focus on data scarcity impacting vaccine hesitancy among immunocompromised individuals.
- The research, conducted through a global online survey of over 7200 individuals, found that SLE patients experienced significantly more major DAEs and hospitalizations post-vaccination than healthy controls and had higher rates of severe rashes compared to those with other rheumatic diseases.
- The findings suggest a need for careful monitoring of SLE patients post-vaccination due to their elevated risk of adverse events, particularly after receiving the Moderna vaccine.